UnicoCell Biomed Co., Ltd. (TPE:6794)
65.80
+1.30 (2.02%)
Nov 13, 2026, 1:23 PM CST
UnicoCell Biomed Revenue
UnicoCell Biomed had revenue of 4.60M TWD in the quarter ending June 30, 2026, a decrease of -47.00%. This brings the company's total for the last twelve months to 22.46M, down -48.98% year-over-year. In the year 2025, UnicoCell Biomed had annual revenue of 30.10M, down -5.58%. That makes UnicoCell Biomed the 44,188th largest company in the world by revenue and 2,173rd in Taiwan.
Revenue (ttm)
22.46M
Revenue Growth
-48.98%
P/S Ratio
186.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.19B
Revenue by Geography
- Taiwan 28.07M 93.2%
- Japan 2.04M 6.8%
Fiscal year ended Dec 31, 2025 See the full UnicoCell Biomed breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.10M | -1.78M | -5.58% |
| Dec 31, 2024 | 31.88M | 7.29M | 29.66% |
| Dec 31, 2023 | 24.59M | 10.19M | 70.79% |
| Dec 31, 2022 | 14.40M | 6.22M | 76.07% |
| Dec 31, 2021 | 8.18M | 4.20M | 105.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.55B |
| SYN-TECH Chem. & Pharm. | 1.30B |
| Mycenax Biotech | 815.87M |
| Sagittarius Life Science | 467.69M |
| Pharmosa Biopharm | 54.19M |
| Formosa Pharmaceuticals | 51.67M |
| BRIM Biotechnology | 12.55M |
| Great Novel Therapeutics Biotech & Medicals | 6.21M |